Citigroup Issues Pessimistic Forecast for Integra LifeSciences (NASDAQ:IART) Stock Price

Integra LifeSciences (NASDAQ:IART) had its target price dropped by stock analysts at Citigroup from $12.00 to $11.00 in a research report issued on Friday,Benzinga reports. The firm currently has a “sell” rating on the life sciences company’s stock. Citigroup’s target price would suggest a potential downside of 8.41% from the company’s current price.

A number of other equities analysts also recently weighed in on IART. Truist Financial set a $15.00 target price on Integra LifeSciences and gave the company a “hold” rating in a report on Wednesday, October 15th. Weiss Ratings reiterated a “sell (d)” rating on shares of Integra LifeSciences in a report on Wednesday, October 8th. Finally, JPMorgan Chase & Co. increased their price objective on Integra LifeSciences from $12.00 to $13.00 and gave the stock an “underweight” rating in a report on Friday. Two analysts have rated the stock with a Buy rating, two have assigned a Hold rating and four have given a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Reduce” and an average target price of $16.17.

Integra LifeSciences Price Performance

Shares of IART opened at $12.01 on Friday. The company has a market capitalization of $935.71 million, a price-to-earnings ratio of -1.84 and a beta of 1.21. Integra LifeSciences has a fifty-two week low of $11.05 and a fifty-two week high of $27.13. The company has a debt-to-equity ratio of 1.18, a current ratio of 1.23 and a quick ratio of 0.73. The business’s 50-day moving average is $14.70 and its 200-day moving average is $13.81.

Integra LifeSciences (NASDAQ:IART) last issued its earnings results on Thursday, October 30th. The life sciences company reported $0.54 earnings per share for the quarter, beating analysts’ consensus estimates of $0.43 by $0.11. The company had revenue of $402.06 million for the quarter, compared to the consensus estimate of $414.31 million. Integra LifeSciences had a positive return on equity of 12.15% and a negative net margin of 30.87%.The firm’s quarterly revenue was up 5.6% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.41 EPS. Integra LifeSciences has set its Q4 2025 guidance at 0.790-0.840 EPS. FY 2025 guidance at 2.190-2.240 EPS. Equities research analysts expect that Integra LifeSciences will post 2.45 EPS for the current fiscal year.

Hedge Funds Weigh In On Integra LifeSciences

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Amalgamated Bank grew its holdings in Integra LifeSciences by 3.8% during the third quarter. Amalgamated Bank now owns 19,809 shares of the life sciences company’s stock valued at $284,000 after purchasing an additional 728 shares during the last quarter. Arizona State Retirement System grew its holdings in Integra LifeSciences by 4.2% during the first quarter. Arizona State Retirement System now owns 19,894 shares of the life sciences company’s stock valued at $437,000 after purchasing an additional 795 shares during the last quarter. Wedge Capital Management L L P NC grew its holdings in Integra LifeSciences by 1.2% during the second quarter. Wedge Capital Management L L P NC now owns 70,114 shares of the life sciences company’s stock valued at $860,000 after purchasing an additional 801 shares during the last quarter. Wealth Enhancement Advisory Services LLC grew its holdings in Integra LifeSciences by 6.4% during the third quarter. Wealth Enhancement Advisory Services LLC now owns 14,200 shares of the life sciences company’s stock valued at $205,000 after purchasing an additional 848 shares during the last quarter. Finally, GAMMA Investing LLC grew its holdings in Integra LifeSciences by 55.3% during the third quarter. GAMMA Investing LLC now owns 2,565 shares of the life sciences company’s stock valued at $37,000 after purchasing an additional 913 shares during the last quarter. Institutional investors and hedge funds own 84.78% of the company’s stock.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.